GlassScriptPhysician profile
Devarajan P Iyengar
NPI 1689620700
$3,913.66
in general payments reported to CMS, 2019-2025
47 companies · $1,027 in 2025
The $1,027 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $571 · 2020: $357 · 2021: $640 · 2022: $101 · 2023: $541 · 2024: $676 · 2025: $1,027.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,945 · Education: $299.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,945.36 |
| Education | $298.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $521.45 | 2019-2025 | Darzalex, Talvey, Tecvayli |
| Amgen INC. | $375.37 | 2019-2025 | Evenity, Prolia |
| Merck Sharp & Dohme LLC | $327.43 | 2019-2025 | Keytruda, Lynparza |
| Pfizer INC. | $289.24 | 2019-2025 | |
| Exelixis INC. | $257.53 | 2019-2025 | |
| Astellas Pharma US INC | $221.97 | 2019-2023 | Padcev |
| Bayer Healthcare Pharmaceuticals INC. | $187.63 | 2019-2025 | |
| Lilly USA, LLC | $170.82 | 2019-2025 | Verzenio, Jaypirca |
| Array Biopharma INC | $120.46 | 2020-2025 | Braftovi, Mektovi, Lorbrena |
| E.R. Squibb & Sons, L.L.C. | $116.75 | 2020-2025 | Opdivo, Reblozyl |
| Abbvie INC. | $111.38 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $104.85 | 2019-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $84.95 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $74.73 | 2019-2021 | |
| Celgene Corporation | $71.80 | 2022-2024 | Reblozyl |
Show all 46 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Devarajan Iyengar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.